All In Biotech

Drug Trial Radar · NCT07895394

Immunogenicity and Safety of Respiratory Syncytial Virus Vaccine in Lung Transplant Recipients

Analysis of Vaccine-induced Immune Responses and Optimization of Protective Immunity Against Respiratory Syncytial Virus in Lung Transplant Recipients

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Oct 27, 2026

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
Seoul National University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the immunogenicity and safety of respiratory syncytial virus (RSV) vaccination between lung transplant recipients and immunocompetent adults and to provide evidence to guide RSV vaccination in lung transplant recipients.

Conditions

  • Vaccination
  • Respiratory Syncytial Virus (RSV)
  • Lung Transplant Recipient

Interventions

  • RSVPreF3 vaccinationBiological

    One dose of RSVPreF3 (Arexvy®) vaccine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Humoral immune response (neutralizing antibody)Time frame: 1 month after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Seoul National University Hospital

    Seoul, Jongno-Gu, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.